Recent Quotes (30 days)

You have no recent quotes
chg | %

BioCryst Pharmaceuticals, Inc.  

(Public, NASDAQ:BCRX)   Watch this stock  
-0.01 (-0.20%)
Real-time:   9:40AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.04 - 5.11
52 week 3.75 - 9.25
Open 5.11
Vol / Avg. 0.00/2.42M
Mkt cap 410.38M
P/E     -
Div/yield     -
EPS -0.62
Shares 80.43M
Beta 3.36
Inst. own 87%
Nov 6, 2017
Q3 2017 BioCryst Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 27, 2017
BioCryst Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 26, 2017
BioCryst Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference
Sep 6, 2017
BioCryst Pharmaceuticals Inc at Robert W Baird Gobal Healthcare Conference - Webcast
Sep 5, 2017
BioCryst Pharmaceuticals Inc Announces Positive Results from its APeX-1 Phase 2 Trial in HAE Call - Webcast
Aug 7, 2017
Q2 2017 BioCryst Pharmaceuticals Inc Earnings Call - Webcast
Aug 7, 2017
Q2 2017 BioCryst Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -544.89% -209.25%
Operating margin -500.68% -184.45%
EBITD margin - -182.61%
Return on average assets -55.74% -51.97%
Return on average equity -216.37% -223.70%
Employees 65 -
CDP Score - -


4505 Emperor Blvd Ste 200
DURHAM, NC 27703-8457
United States - Map
+1-919-8591302 (Phone)
+1-919-8591314 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Officers and directors

Robert A. Ingram Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Jon P. Stonehouse President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Thomas R. Staab II Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
Age: 70
Bio & Compensation  - Reuters
Yarlagadda S. Babu Ph.D. Senior Vice President - Drug Discovery
Age: 62
Bio & Compensation  - Reuters
Lynne M Powell Senior Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
William P. Sheridan Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Alane P. Barnes Vice President, General Counsel, and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D. M.D. Director
Age: 60
Bio & Compensation  - Reuters
Sanj K. Patel Director
Age: 48
Bio & Compensation  - Reuters
George B. Abercrombie Independent Director
Age: 61
Bio & Compensation  - Reuters